Dexa Group Fosters Natural Medicine MSMEs, BPOM Appreciates Natural Medicine Manufacturers through Strengthening Independence

Dexa Group and other Natural Medicine (OBA) industries have received appreciation from the Indonesian Food and Drug Authority (BPOM) for becoming foster parents that provide education and training for the development of OBA for MSME manufacturers. This initiative is expected to strengthen the acceleration of pharmaceutical independence in Indonesia.

The signing of the MSME Foster Parent Program for Natural Medicine and Cosmetics took place at the Indonesia Wellness Festival (Wellfest) 2024, held at Central Park Mall, Jakarta, on August 2, 2024. The commitment from Dexa Group was signed by the Business Development and Scientific Affairs Director of Dexa Group, Prof. Raymond Tjandrawinata, and witnessed by Acting Head of BPOM, Mrs. Rizka Andalucia.

Mrs. Rizka Andalucia stated that this program involves 6 cosmetic industries and 8 natural medicine industries committed to becoming foster parents for MSMEs in natural medicine and cosmetics. Through this program, natural medicine and cosmetics industries provide mentoring to MSMEs in areas such as licensing, facility standards, product quality, technology, and marketing, enabling MSMEs to meet regulations and grow faster with higher competitiveness.

According to Prof. Raymond, with the signing of this commitment, Dexa Group will provide support in the form of education and knowledge sharing to MSME manufacturers of natural medicines.

“This is a good synergy among manufacturers. Dexa Group expresses its support to develop the natural medicine ecosystem, which has significant potential both in Indonesia and globally,” said Prof. Raymond.

Prof. Raymond added that this effort could help natural medicine products in Indonesia become leading market domestically and compete in the global market.

To further promote the use of natural medicines and achieve a level similar to the use of ginseng in South Korea, traditional medicine in China, and Ayurveda in India, the utilization of Indonesia Indigenous Modern Medicine (OMAI) phytopharmaca needs to be encouraged more widely.

“Therefore, OMAI Phytopharmaca should be promoted for inclusion in the National Formulary so it can be prescribed by doctors. Phytopharmaca is Indonesia’s strength, being a medicine developed by Indonesian scientists utilizing indigenous materials, and it is time for it to be used by JKN patients,” emphasized Prof. Raymond.

In addition to the signing of the MSME Foster Parent Program for Natural Medicine and Cosmetics, the Wellfest 2024 event also featured an exhibition of natural medicine products, health supplements, and cosmetics. At the exhibition, Dexa Group showcased OMAI products such as HerbaKOF (cough medicine with ginger, Mahkota Dewa, Legundi leaves, and Saga), STIMUNO (for immune support with meniran), HerbaPain (pain relief with Mahkota Dewa), HerbaVomitz (stomach disorder treatment with ginger), Redacid (stomach disorder treatment with cinnamon), and Inlacin (antidiabetes with cinnamon and bunga bungur). Additionally, beauty products like Seloxy, Prosentials, Achante, and Ascavin were featured.

At the event, Dexa Group also presented a series of children’s books published by Teman Bumil and Teman Parenting.

Dexa Group’s Contribution to Pharmaceutical Independence

The President Director of PT Dexa Medica stated that Dexa Group’s participation in Wellfest 2024 represents a synergy with the government in developing a natural-based health ecosystem.

“As we all know, Indonesia’s natural medicine potential is substantial, and Dexa Group aims to be a significant player in this market. Currently, natural-based medicines produce 31 phytopharmaca, with Dexa Group contributing about 90% of the natural medicines in OMAI Phytopharmaca,” said Mr. V. Hery.

Mr. V. Hery further explained that not only does Dexa Group dominate the phytopharmaca products, but the quality of its products has also been proven by its presence in export markets such as the Philippines, Nigeria, Cambodia, Vietnam, the USA, Mongolia, Singapore, and Timor Leste.

According to Mr. V. Hery, the significant contribution of domestic natural medicines to pharmaceutical independence needs to be supported by government regulations that encourage their inclusion in the National Formulary so they can be utilized by BPJS participants.

Currently, several Dexa Group products have been included in phytopharmaca medicines, namely Stimuno, Inlacin, Redacid, and Disolf.